41 – 50 of 103
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?
(
- Contribution to journal › Article
- 2018
-
Mark
Big Data and intellectual property rights in the health and life sciences
2018) p.311-323(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
A Ray of Light in Muddy Waters? -The CJEU rules on combination SPCs in C-121/17 Teva v Gilead
(
- Contribution to journal › Article
-
Mark
How much is too much?- Defining the Metes and Bounds of Excessive Pricing in the Pharmaceutical Sector
(
- Contribution to journal › Article
-
Mark
Challenges for the sustainability of university-run biobanks
(
- Contribution to journal › Article
-
Mark
Will the EPO’s Enlarged Board of Appeal hear the Broad's CRISPR case?
2018) In Life Sciences Intellectual Property Review (LSIPR)(
- Contribution to journal › Article
-
Mark
Patentability Standards for Follow-on Pharmaceutical Innovation
(
- Contribution to journal › Article
-
Mark
Big Data in the Health and Life Sciences: What Are the Challenges for European Competition Law and Where Can They Be Found?
2018) In CEIPI / ICTSD Publication Series on Global Perspectives and Challenges for the Intellectual Property System p.121-130(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Clearing a way through the CRISPR patent jungle
2018) In Life Sciences Intellectual Property Review (LSIPR)(
- Contribution to journal › Article
-
Mark
Reap what you sow! - But what about SPC squatting?
(
- Contribution to journal › Article